Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that BCR::ABL1 status confers therapeutic sensitivity to Dasatinib in patients with Acute Lymphoblastic Leukemia.

Health Canada approved dasatinib for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.

This statement is based on a regulatory approval from the Health Canada:

SPRYCEL (dasatinib) is indicated for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.

Citation

Bristol-Myers Squibb Canada. Sprycel (dasatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080799.PDF. Revised June 2025. Accessed April 2026.

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals